From a safety perspective, brand-name medications are always a better option
This makes it a valuable tool in managing chronic conditions linked to obesity
Dani SS, Makwana B, Khadke S, Kumar A, Jhund P, Nasir K, Sattar N, Al-Kindi S, Fonarow G, Butler J, Bhatt DL, Kosiborod MN, Nohria A, Ganatra S (2025) An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists
To inquire if we currently carry or can compound your prescription, please fill out the form located on our Contact page or call us at (877) 562-8577
Phase 2 trials, completed in 2023, demonstrated remarkable efficacy across multiple dose levels
Do not start the process and then go searching for supplies